Acesion Pharma Announces Positive Results for Novel Drug Targeting Atrial Fibrillation

  • Phase 1 data show favourable safety profile
  • Data support further development of AP30663 for cardioversion therapy

COPENHAGEN, Denmark — 5 November 2018: Acesion Pharma (“Acesion” or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces positive results from the Phase 1 clinical trial of its lead compound AP30663.

The results of the study demonstrated that intravenous AP30663 was well tolerated with ascending doses, with no significant adverse events.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH